SeraCare is proud to be presenting two scientific posters
at the 2nd AMP Global 2019 Congress in Hong Kong.
Friday, May 17th ~ 10:00 - 10:45 am
Lung cancer is the leading cause of cancer death with a majority diagnosis of non-small cell lung carcinoma (NSCLC). About 10-50% of NSCLCs have one of several activating EGFR driver mutations which have been clinically validated as therapeutic biomarkers for anti-EGFR drugs. Identifying these driver mutations through liquid biopsies is a promising alternative to traditional biopsies; however, the precision of mutation analysis for some of these targets remains a challenge.
Consistent Performance of Highly Multiplexed RNA Fusion Reference Materials
across Different NGS Assays in a Multi-Lab Study
Saturday, May 18th ~ 10:00 - 10:45 am
Fusion detection is an important part of cancer disease management, and there is an increasing need for highly multiplexed reference materials to cover mutations which may be rare or difficult to obtain. SeraCare continues to innovate the Seraseq Fusion RNA product line in order to address this critical market need with an updated version designed for use with NGS assays that detect gene fusions via sequencing of RNA transcripts.
~ ~ ~
Featured Speaker: Omo Clement
Omo Clement is the Sr. Product Marketing Manager in the Clinical Genomics business unit at SeraCare. Dr. Clement has rich product marketing experience and has held roles at Illumina, RainDance Technologies, Asuragen, and in Digital Biology at Bio-Rad Laboratories.